Morgan Stanley Adjusts Earnings Per Share Forecasts for SBP GROUP Through 2028, Reiterates 'Overweight' Rating

Stock News07-14 15:10

Morgan Stanley has issued a research report updating its financial projections for SBP GROUP (01177). The bank has largely maintained its forecasts for the company's innovative drugs. However, it has lowered its sales forecasts for generic drugs and biosimilars, citing the latest sales policies and upcoming volume-based procurement initiatives.

Concurrently, the bank has raised its revenue forecast for commercial licensing deals. This adjustment accounts for the upfront payments from Sanofi and GSK, which are expected to be booked this year, along with potential future milestone payments and new licensing revenue.

The firm's target price remains at HK$7.80, and its 'Overweight' rating is reiterated. However, the bear-case scenario target price has been reduced from HK$4.80 to HK$4.50.

Morgan Stanley has lowered its earnings per share forecasts for SBP GROUP for the years 2026 through 2028 by 2% to 3% each year when excluding commercial licensing revenue. This revision primarily reflects the reduced sales outlook for generic drugs.

When including the projected commercial licensing revenue, the bank's basic earnings per share forecasts for the company for 2026, 2027, and 2028 are increased by 13.6%, 5.5%, and 3.9%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1150857600?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 15:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150857600","market":"hk","top_or_hot":-1,"title":"Morgan Stanley Adjusts Earnings Per Share Forecasts for SBP GROUP Through 2028, Reiterates 'Overweight' Rating","media":"Stock News","content":"<p>Morgan Stanley has issued a research report updating its financial projections for <b>SBP GROUP</b> (<b>01177</b>). The bank has largely maintained its forecasts for the company's innovative drugs. However, it has lowered its sales forecasts for generic drugs and biosimilars, citing the latest sales policies and upcoming volume-based procurement initiatives.<br><br>Concurrently, the bank has raised its revenue forecast for commercial licensing deals. This adjustment accounts for the upfront payments from Sanofi and GSK, which are expected to be booked this year, along with potential future milestone payments and new licensing revenue.<br><br>The firm's target price remains at HK$7.80, and its 'Overweight' rating is reiterated. However, the bear-case scenario target price has been reduced from HK$4.80 to HK$4.50.<br><br>Morgan Stanley has lowered its earnings per share forecasts for <b>SBP GROUP</b> for the years 2026 through 2028 by 2% to 3% each year when excluding commercial licensing revenue. This revision primarily reflects the reduced sales outlook for generic drugs.<br><br>When including the projected commercial licensing revenue, the bank's basic earnings per share forecasts for the company for 2026, 2027, and 2028 are increased by 13.6%, 5.5%, and 3.9%, respectively.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley Adjusts Earnings Per Share Forecasts for SBP GROUP Through 2028, Reiterates 'Overweight' Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley Adjusts Earnings Per Share Forecasts for SBP GROUP Through 2028, Reiterates 'Overweight' Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-14 15:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Morgan Stanley has issued a research report updating its financial projections for <b>SBP GROUP</b> (<b>01177</b>). The bank has largely maintained its forecasts for the company's innovative drugs. However, it has lowered its sales forecasts for generic drugs and biosimilars, citing the latest sales policies and upcoming volume-based procurement initiatives.<br><br>Concurrently, the bank has raised its revenue forecast for commercial licensing deals. This adjustment accounts for the upfront payments from Sanofi and GSK, which are expected to be booked this year, along with potential future milestone payments and new licensing revenue.<br><br>The firm's target price remains at HK$7.80, and its 'Overweight' rating is reiterated. However, the bear-case scenario target price has been reduced from HK$4.80 to HK$4.50.<br><br>Morgan Stanley has lowered its earnings per share forecasts for <b>SBP GROUP</b> for the years 2026 through 2028 by 2% to 3% each year when excluding commercial licensing revenue. This revision primarily reflects the reduced sales outlook for generic drugs.<br><br>When including the projected commercial licensing revenue, the bank's basic earnings per share forecasts for the company for 2026, 2027, and 2028 are increased by 13.6%, 5.5%, and 3.9%, respectively.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000165453.HKD","symbol_name":"华夏精选大中华科技基金 A类港币","start_time":0,"source_url":"","article_id":"1150857600","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150857600","pubTimestamp":1784013021,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Morgan Stanley has issued a research report updating its financial projections for SBP GROUP (01177). The bank has largely maintained its forecasts for the company's innovative drugs. However, it has...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","BK1521":"挪威政府全球养老基金持仓","BK1589":"北水核心资产","BK1191":"制药","BK1515":"抗疫概念","01477":"欧康维视生物-B","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","01177":"中国生物制药","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1574":"生物医药B类股"},"translate_title":"摩根士丹利调整 SBP 集团到 2028 年的每股收益预测，重申“跑赢大盘”评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"01177":1},"content_text":"Morgan Stanley has issued a research report updating its financial projections for SBP GROUP (01177). The bank has largely maintained its forecasts for the company's innovative drugs. However, it has lowered its sales forecasts for generic drugs and biosimilars, citing the latest sales policies and upcoming volume-based procurement initiatives.Concurrently, the bank has raised its revenue forecast for commercial licensing deals. This adjustment accounts for the upfront payments from Sanofi and GSK, which are expected to be booked this year, along with potential future milestone payments and new licensing revenue.The firm's target price remains at HK$7.80, and its 'Overweight' rating is reiterated. However, the bear-case scenario target price has been reduced from HK$4.80 to HK$4.50.Morgan Stanley has lowered its earnings per share forecasts for SBP GROUP for the years 2026 through 2028 by 2% to 3% each year when excluding commercial licensing revenue. This revision primarily reflects the reduced sales outlook for generic drugs.When including the projected commercial licensing revenue, the bank's basic earnings per share forecasts for the company for 2026, 2027, and 2028 are increased by 13.6%, 5.5%, and 3.9%, respectively.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1150857600","isCrawlerRequest":true}